Outset Medical Insider Sales Show Tax‑Cover Moves Amid Strong Dialysis Trial and FDA Breakthrough
Outset Medical’s insider sell‑to‑cover activity shows no loss of confidence; with breakthrough device status and Phase IIb gains, investors should watch upcoming FDA/EMA decisions and the CEO’s J.P. Morgan conference for future valuation clues.
4 minutes to read